bay-87-2243 and Pancreatic-Neoplasms

bay-87-2243 has been researched along with Pancreatic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bay-87-2243 and Pancreatic-Neoplasms

Article	Year
Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. Journal of medicinal chemistry, 2022, 01-13, Volume: 65, Issue:1 Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy for select cancers that are dependent on aerobic metabolism. Here, we report the discovery, optimization, and structure-activity relationship (SAR) study of a series of novel OXPHOS inhibitors. The hit compound, benzene-1,4-disulfonamide Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discovery; Female; Humans; Mice; Mice, Inbred C57BL; Oxidative Phosphorylation; Pancreatic Neoplasms; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2022

Article

Year

Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

Journal of medicinal chemistry, 2022, 01-13, Volume: 65, Issue:1

Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy for select cancers that are dependent on aerobic metabolism. Here, we report the discovery, optimization, and structure-activity relationship (SAR) study of a series of novel OXPHOS inhibitors. The hit compound, benzene-1,4-disulfonamide

Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discovery; Female; Humans; Mice; Mice, Inbred C57BL; Oxidative Phosphorylation; Pancreatic Neoplasms; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2022